Merck To Focus Taranabant Development On Lower Dose
Cannabinoid-1 receptor blocker shows weight loss benefits with lower adverse psychiatric events at 2 mg dose in Phase III.
Cannabinoid-1 receptor blocker shows weight loss benefits with lower adverse psychiatric events at 2 mg dose in Phase III.